Mar 16 |
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
|
Mar 12 |
atai Life Sciences advances VLS-01 for treatment-resistant depression
|
Mar 4 |
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
|
Feb 28 |
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
|
Feb 12 |
Psychedelic stocks gain after FDA priority review for MDMA therapy
|
Feb 6 |
Atai Life Sciences names Anne Johnson as its CFO
|
Feb 6 |
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
|
Jan 27 |
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
|
Jan 12 |
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
|
Jan 9 |
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
|